{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965516",
  "id": "02965516",
  "pages": 1,
  "price_sensitive": false,
  "date": "20250703",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250703/pdf/06lf4cshwnz5xf.pdf",
  "summary": "- **Key milestone**: Commencement of manufacturing for **IRX-211**, InhaleRx's lead investigational product, for an upcoming **Phase 2 trial in breakthrough cancer pain (BTcP)**.  \n- **Manufacturing partner**: **Ab Initio Pharma** (GMP-certified, Sydney-based).  \n- **Funding**: Fully funded trial, with a secured facility of **up to $38.5m** for IRX-211 and other pipeline assets.  \n- **Next update**: Progress toward **first patient enrollment** in the Phase 2 trial.  \n\n*No material trading or capital markets actions (e.g., raising, timetable) identified.*",
  "usage": {
    "prompt_tokens": 878,
    "completion_tokens": 139,
    "total_tokens": 1017,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-03T00:01:42.952673"
}